Preview

Современная ревматология

Расширенный поиск

Фенотипические особенности и клиническая неоднородность антисинтетазного синдрома

https://doi.org/10.14412/1996-7012-2013-12

Полный текст:

Аннотация

Наиболее тяжелым подтипом полимиозита и дерматомиозита (ПМ/ДМ) является антисинтетазный синдром (АСС), ассоциированный с наличием специфических иммунологических маркеров в сыворотке крови – антисинтетазных антител (анти-Jо1, анти-PL7, анти-PL12 и др.). АСС имеет определенные фенотипические особенности, отличающие его от группы ПМ/ДМ в целом. Наибольшее клиническое значение придается интерстициальному поражению легких, определяющему терапевтическую тактику и прогноз. Кроме того, течение болезни у некоторых пациентов с АСС отличается не только от такового при ПМ/ДМ в целом, но и непосредственно внутри подгруппы с АСС, что свидетельствует о клинической неоднородности последнего и имеет как научный, так и практический интерес.

Об авторах

Ольга Алексеевна Антелава
Кафедра ревматологии ФППОВ ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России
Россия


Евгений Львович Насонов
ФГБУ «Научно-исследовательский институт ревматологии им. акад. В.А. Насоновой» РАМН, Москва
Россия


Литература

1. <div><p>Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N EngI J Med. 1975;(292):344–7.</p><p>Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;(292):403.</p><p>Антелава ОА. Идиопатические воспалительные миопатии. Ревматология национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой М.: ГЭОТАР-Медиа, 2008;502–17. [Antelava OA. Idiopaticheskie vospalitel'nye</p><p>miopatii. Revmatologiya natsional'noe rukovodstvo. Under edition of Nasonova EL, Nasonovoy VA. Moscow: GEOTAR-Media, 2008;502–17.]</p><p>Solomon J, Swigris JJ, Brown KK. Myositisrelated interstitial lung disease and antisynthetase syndrome. J Bras Pneumol.</p><p>;(37):100–9.</p><p>Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;(362):971.</p><p>Plotz PH, Dalakas M, Leff RL et al. Current concepts in the idiopathic inflammatory myopathies: Polymyositis, dermatomyositis and related disorders. Ann Int Med. 1989;111–43.</p><p>Marguerie C, Bunn CC, Beynon HL et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77(282):1019–38.</p><p>Mileti LM, Strek ME, Niewold TB et al. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheum. 2009;15(5):254–5.</p><p>Mielnik P, Wiesik-Szewczyk E, Olesinska M et al. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity.</p><p>;39(3):243–7.</p><p>Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous</p><p>patient groups. Medicine (Baltimore). 1991;70(6):360–74.</p><p>Hirsch TJ, Enlow RW, Bias WB, Arnett FC. HLA-D related (DR) antigens in various kinds of myositis. Hum Immunol. 1981;3(2):181–6.</p><p>Lega JC, Cottin V, Fabien N et al. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheum. 2010;37(5):1000–9.</p><p>Mahler M, Raijmakers R, DКhnrich C et al. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthr Res Ther. 2005;7(3):704–13.</p><p>Ghirardello A, Zampieri S, Iaccarino L et al. Anti-Mi-2 antibodies. Autoimmunity. 2005;38(1):79–83.</p><p>Hengstman GJ, van Engelen BG, van Venrooij W. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheum. 2004;16(6):692–9.</p><p>Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthr Rheum.</p><p>;33(9):1361–70.</p><p>Антелава ОА, Тарасова ГМ, Сажина ЕГ и др. Антисинтетазный синдром – наиболее тяжелый подтип полимиозита/дерматомиозита (описание случаев). Современная ревматология. 2009;(4):54–8. [Antelava OA, Tarasova GM, Sazhina EG et al. Antisynthetase syndrome is the most severe subtype of polymyositis/dermatomyositis: description of cases. Sovremennaya revmatologiya. 2009;(4):54–8.]</p><p>Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome.Curr Rheum Rep. 2011;(13):175–81.</p><p>Антелава ОА, Балабанова РМ, Сажина ЕГ и др. Особенности дебюта и течения антисинтетазного синдрома как наиболее тяжелого подтипа полимиозита/дерматомиозита. Российский медицинский журнал. 2009;17(21):1443–7. [Antelava OA, Balabanova RM, Sazhina EG i dr. Osobennosti debyuta i techeniya antisintetaznogo sindroma kak naibolee tyazhelogo podtipapolimiozita/dermatomiozita. Rossiyskiy meditsinskiy zhurnal. 2009;17(21):1443–7.]</p><p>Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheum. 2010;(22):633–8.</p><p>Ананьева ЛП, Волков АВ, Смирнов АВ, Антелава ОА. Поражение органов дыхания при системных заболеваниях соединительной ткани. В кн.: Респираторная медицина.</p><p>Под ред. А.Г.Чучалина. М.: ГЭОТАР-Медиа; 2007;(2):251–68. [Anan'eva LP, Volkov AV, Smirnov AV, Antelava OA. Porazhenie organov dykhaniya pri sistemnykh zabolevaniyakh soedinitel'noy tkani. In the book: Respiratornaya meditsina. Under edition of Chuchalina AG. Moscow: GEOTAR-Media;</p><p>;(2):251–68.]</p><p>Антелава ОА, Бондаренко ИБ, Хитров АН, Насонов ЕЛ. Поражение дыхательной системы при полимиозите/дерматомиозите. Российский медицинский журнал. 2008;16,24(334):1633–7. [Antelava OA, Bondarenko IB, Khitrov AN, Nasonov EL. Porazhenie dykhatel'noy sistemy pripolimiozite/dermatomiozite. Rossiyskiy meditsinskiy zhurnal. 2008;16,24(334):1633–7.]</p><p>Koreeda Y, Higashimoto I, Yamamoto M et al. Clinical and pathological findings of interstitial lung disease patients with antiaminoacyl tRNA synthetase autoantibodies. Int Med.</p><p>;49(5):361–9.</p><p>Tillie-Leblond I, Wislez M, Valeyre D et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63(1):53–9.</p><p>Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry. 2000;68(4):472–8.</p><p>Guglielmi S, Merz TM, Gugger M et al. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J. 2008;31(1):213–7.</p><p>Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthr Rheum. 1995;38(10):1519–23.</p><p>Fischer A, Swigris JJ, du Bois RM et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med.</p><p>;103(11):1719–24.</p><p>Mileti LM, Strek ME, Niewold TВ et al. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheum. 2009;15(5):254–5.</p><p>Sauty A, Rochat T, Schoch OD et al. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1-antibodies. Eur Respir J. 1997;10(12):2907–12.</p><p>Watanabe K, Handa T, Tanizawa K et al. Prevalence of autoantibodies to aminoacyltransfer RNA synthetases (ARS) among patients who were diagnosed with idiopathic interstitial</p><p>pneumonias (IIPs) [abstract]. Am J Respir Crit Care Med. 2010;(181):2354.</p><p>Hervier B, Devilliers H, Stanciu R et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase</p><p>antibody specificity. Autoimmun Rev. 2012; [Epub ahead of print].</p><p>Hervier B, Wallaert B, Hachulla E et al. Clinical manifestations of antisynthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford). 2010;49(5):972–6.</p><p>Kalluri M, Sahn SA, Oddis CV et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009;135(6):1550–6.</p><p>Handa T, Nagai S, Kawabata D et al. Longterm clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Int Med. 2005;44(4):319–25.</p><p>Hirakata M, Nakamura Y, Okano Y et al. Anti-alanyl tRNA synthetase (PL-12) antibodies are associated with interstitial lung disease in Japanese patients [abstract]. Arthr Rheum.</p><p>;(38):321.</p><p>Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthr Rheum. 1996;26(1):459–67.</p><p>Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med. 1990;88(3):241–51.</p><p>Schmidt WA, Wetzel W, FriedlКnder R et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies – an evolving spectrum of disease manifestations. Clin Rheum.</p><p>;19(5):371–7.</p><p>Marguerie C, Bunn CC, Beynon HL et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77(282):1019–38.</p><p>Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNA Ala coexist and are associated with myositis. J Exp Med. 1986;163(5):1281–91.</p><p>Schnabel A, Reuter M, Biederer J et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthr Rheum. 2003;32(5):273–84.</p><p>Tillie-Leblond I, Wislez M, Valeyre D et al. Interstitial lung disease and anti- Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63(1):53–9.</p><p>Stanciu R, Guiguet M, Musset L et al. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheum. 2012;39(9):1835–9. DOI: 10.3899/jrheum.111604 Epub 2012 Aug 1.</p><p>Salmeron G, Greenberg SD, Lidsky MD. Polymyositis and diffuse interstitial lung disease. A review of the pulmonary histopathologic findings. Arch Int Med. 1981;141(8):1005–10.</p><p>Антелава ОА, Насонов ЕЛ. Ритуксимаб в лечении идиопатических воспалительных миопатий. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. М.: ИМА-ПРЕСС; 2012;178–89. [Antelava OA, Nasonov EL. Rituksimab v lechenii idiopaticheskikh vospalitel'nykh miopatiy. Anti-V-kletochnaya terapiya v revmatologii: fokus na rituksimab. Under edition of</p><p>Nasonova EL. Moscow: IMA-PRESS; 2012;178–89.</p><p>Lambotte O, Kotb R, Maigne G et al. Efficacy of rituximab in refractory polymyositis. J Rheum. 2005;(32):1369–70.</p><p>Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis. 2006;(65):974–5.</p><p>Vandenbroucke E, Grutters JC, Altenburg J et al. Rituximab in life threatening antisynthetase syndrome. Rheum Int. 2009;(29):1499–502.</p><p>Frikha F, Rigolet A, Behin A et al. Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases. Rheumatology (Oxford). 2009;(48):1166–8.</p><p>Sem M, Molberg O, Lund MB et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology(Oxford). 2009;(48):968–71.</p><p>Ball EMA, Savage EM, Pendleton A. Refractory anti-synthetase syndrome treated with rituximab. Rheumatology (Oxford). 2010;(49):1013.</p><p>Frazier AR, Miller RD. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest. 1974;65(4):403–7.</p><p>Douglas WW, Tazelaar HD, Hartman TE et al. Polymyositis/dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164(7):1182–5.</p><p>Yoshifuji H, Fujii T, Kobayashi S et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory</p><p>myopathies. Autoimmunity. 2006;39(3):233–41.</p><p>Marie I, Hachulla E, ChОrin P et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthr Rheum. 2002;47(6):614–22.</p><p>Nawata Y, Kurasawa K, Takabayashi K et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheum. 1999;26(7):1527–33.</p><p>Tanaka F, Origuchi T, Migita K et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Int Med. 2000;39(5):428–30.</p><p>Yoshida T, Koga H, Saitoh F et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Int Med.</p><p>;38(9):733–8.</p></div><br />


Для цитирования:


Антелава О.А., Насонов Е.Л. Фенотипические особенности и клиническая неоднородность антисинтетазного синдрома. Современная ревматология. 2013;7(3):41-46. https://doi.org/10.14412/1996-7012-2013-12

Просмотров: 646


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)